NRIX insider transaction filings
Nurix Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-05. Screen NRIX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-05 | 4 | Hansen Gwenn — Chief Scientific Officer | Option exercise (M): 4,356 @ $1.86 · Sale (S): 4,356 @ $25 · Option exercise (M): 4,356 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Hansen Gwenn — Chief Scientific Officer | Sale (S): 1,500 @ $23.87 · Sale (S): 2,611 @ $24.64 | EDGAR |
| 2026-08-04 | 4 | van Houte Hans — Chief Financial Officer | Sale (S): 1,794 @ $23.89 · Sale (S): 2,967 @ $24.65 | EDGAR |
| 2026-08-03 | 4 | Ring Christine — Chief Legal Officer | Option exercise (M): 5,787 @ $8.72 · Sale (S): 16,589 @ $23.05 · Option exercise (M): 5,787 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | van Houte Hans — Chief Financial Officer | Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Option exercise (M): 3,572 @ $0 · Sale (S): 2,845 @ $23.38 · Option exercise (M): 3,750 (derivative) @ $0 · Option exercise (M): 2,858 (derivative) @ $0 · +1 more | EDGAR |
| 2026-07-30 | 4 | Ring Christine — Chief Legal Officer | Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Option exercise (M): 3,572 @ $0 · Sale (S): 3,847 @ $23.38 · Option exercise (M): 3,750 (derivative) @ $0 · Option exercise (M): 2,858 (derivative) @ $0 · +1 more | EDGAR |
| 2026-07-30 | 4 | Hansen Gwenn — Chief Scientific Officer | Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Option exercise (M): 3,572 @ $0 · Sale (S): 3,847 @ $23.38 · Option exercise (M): 3,750 (derivative) @ $0 · Option exercise (M): 2,858 (derivative) @ $0 · +1 more | EDGAR |
| 2026-07-02 | 4 | Ring Christine — Chief Legal Officer | Option exercise (M): 5,221 @ $1.86 · Option exercise (M): 5,787 @ $8.72 · Sale (S): 11,008 @ $23.56 · Option exercise (M): 5,221 (derivative) @ $0 · Option exercise (M): 5,787 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Ring Christine — Chief Legal Officer | Option exercise (M): 13,333 @ $7.26 · Option exercise (M): 15,602 @ $8.72 · Sale (S): 28,935 @ $20.06 · Option exercise (M): 13,333 (derivative) @ $0 · Option exercise (M): 15,602 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Hansen Gwenn — Chief Scientific Officer | Sale (S): 5,394 @ $20 | EDGAR |
| 2026-06-02 | 4 | Ring Christine — Chief Legal Officer | Option exercise (M): 3,422 @ $1.86 · Sale (S): 8,148 @ $16.60 · Option exercise (M): 3,422 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Saltzman Edward C — Director | Grant/award (A): 31,250 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | DANSEY ROGER D — Director | Grant/award (A): 31,250 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Lacey David L. — Director | Grant/award (A): 31,250 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Kapur Anil — Director | Grant/award (A): 31,250 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Baynes Roy D. — Director | Grant/award (A): 31,250 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Silva Paul M — Director | Grant/award (A): 31,250 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Reinsdorf Judith A — Director | Grant/award (A): 31,250 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | GREGORY JULIA P — Director | Grant/award (A): 31,250 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | van Houte Hans — Chief Financial Officer | Sale (S): 13,473 @ $16.58 · Sale (S): 582 @ $17.18 | EDGAR |
| 2026-05-04 | 4 | Ring Christine — Chief Legal Officer | Sale (S): 8,148 @ $16.96 | EDGAR |
| 2026-05-01 | 4 | Ring Christine — Chief Legal Officer | Sale (S): 5,394 @ $16.76 | EDGAR |
| 2026-04-30 | 4 | van Houte Hans — Chief Financial Officer | Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Sale (S): 2,388 @ $16.65 · Option exercise (M): 2,000 (derivative) @ $0 · Option exercise (M): 3,750 (derivative) @ $0 · +1 more | EDGAR |
| 2026-04-30 | 4 | Ring Christine — Chief Legal Officer | Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Sale (S): 3,214 @ $16.65 · Option exercise (M): 2,000 (derivative) @ $0 · Option exercise (M): 3,750 (derivative) @ $0 · +1 more | EDGAR |
| 2026-04-30 | 4 | Hansen Gwenn — Chief Scientific Officer | Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Sale (S): 3,214 @ $16.65 · Option exercise (M): 2,000 (derivative) @ $0 · Option exercise (M): 3,750 (derivative) @ $0 · +1 more | EDGAR |
| 2026-04-02 | 4 | Ring Christine — Chief Legal Officer | Sale (S): 8,148 @ $15.24 | EDGAR |
| 2026-03-02 | 4 | Ring Christine — Chief Legal Officer | Sale (S): 8,148 @ $15.44 | EDGAR |
| 2026-02-10 | 4 | van Houte Hans — Chief Financial Officer | Grant/award (A): 93,750 (derivative) @ $0 · Grant/award (A): 42,875 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Ring Christine — Chief Legal Officer | Grant/award (A): 93,750 (derivative) @ $0 · Grant/award (A): 42,875 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Hansen Gwenn — Chief Scientific Officer | Grant/award (A): 93,750 (derivative) @ $0 · Grant/award (A): 42,875 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | SANDS ARTHUR T — President, CEO, Director | Grant/award (A): 562,500 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Ring Christine — Chief Legal Officer | Sale (S): 14,261 @ $16.66 | EDGAR |
| 2026-02-03 | 4 | Hansen Gwenn — Chief Scientific Officer | Option exercise (M): 31,333 @ $0.84 · Option exercise (M): 31,333 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | van Houte Hans — Chief Financial Officer | Option exercise (M): 2,887 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,859 @ $0 · Sale (S): 3,588 @ $16.58 · Sale (S): 73 @ $17.37 · +4 more | EDGAR |
| 2026-01-30 | 4 | Ring Christine — Chief Legal Officer | Option exercise (M): 1,925 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,859 @ $0 · Sale (S): 4,333 @ $16.58 · Sale (S): 88 @ $17.37 · +4 more | EDGAR |
| 2026-01-30 | 4 | Hansen Gwenn — Chief Scientific Officer | Option exercise (M): 3,207 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,859 @ $0 · Sale (S): 4,797 @ $16.58 · Sale (S): 98 @ $17.37 · +4 more | EDGAR |
| 2026-01-20 | 4 | Ring Christine — Chief Legal Officer | Option exercise (M): 3,760 @ $1.86 · Sale (S): 3,760 @ $18.42 · Option exercise (M): 3,760 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Ring Christine — Chief Legal Officer | Option exercise (M): 3,760 @ $1.86 · Sale (S): 3,560 @ $17.87 · Sale (S): 200 @ $18.55 · Option exercise (M): 3,760 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | Ring Christine — Chief Legal Officer | Option exercise (M): 37,600 @ $1.86 · Sale (S): 37,600 @ $17.07 · Option exercise (M): 37,600 (derivative) @ $0 | EDGAR |
| 2025-11-10 | 4 | DANSEY ROGER D — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-11-03 | 4 | van Houte Hans — Chief Financial Officer | Sale (S): 6,284 @ $12.56 | EDGAR |
| 2025-10-30 | 4 | van Houte Hans — Chief Financial Officer | Option exercise (M): 2,886 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Sale (S): 3,130 @ $12.80 · Option exercise (M): 2,886 (derivative) @ $0 · +3 more | EDGAR |
| 2025-10-30 | 4 | Ring Christine — Chief Legal Officer | Option exercise (M): 1,924 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Sale (S): 3,644 @ $12.80 · Option exercise (M): 1,924 (derivative) @ $0 · +3 more | EDGAR |
| 2025-10-30 | 4 | Hansen Gwenn — Chief Scientific Officer | Option exercise (M): 3,207 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Sale (S): 4,087 @ $12.80 · Option exercise (M): 3,207 (derivative) @ $0 · +3 more | EDGAR |
| 2025-10-23 | 4 | Hansen Gwenn — Chief Scientific Officer | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-09-17 | 4 | GREGORY JULIA P — Director | Option exercise (M): 10,750 @ $1.86 · Option exercise (M): 10,750 (derivative) @ $0 | EDGAR |
| 2025-08-01 | 4 | van Houte Hans — Chief Financial Officer | Sale (S): 5,402 @ $11.03 | EDGAR |
| 2025-07-30 | 4 | van Houte Hans — Chief Financial Officer | Option exercise (M): 2,886 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Sale (S): 4,304 @ $12.01 · Option exercise (M): 2,886 (derivative) @ $0 · +3 more | EDGAR |
| 2025-07-30 | 4 | Ring Christine — Chief Legal Officer | Option exercise (M): 1,924 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Sale (S): 3,841 @ $12.01 · Option exercise (M): 1,924 (derivative) @ $0 · +3 more | EDGAR |
| 2025-07-30 | 4 | Hansen Gwenn — Chief Scientific Officer | Option exercise (M): 3,207 @ $0 · Option exercise (M): 2,000 @ $0 · Option exercise (M): 3,750 @ $0 · Option exercise (M): 2,858 @ $0 · Sale (S): 4,308 @ $12.01 · Option exercise (M): 3,207 (derivative) @ $0 · +3 more | EDGAR |
Recent 8-K events — Nurix Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-09 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NRIX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →